| 24小時(shí)熱門版塊排行榜 |
| 查看: 3956 | 回復(fù): 16 | ||||
wachina至尊木蟲 (知名作家)
|
[交流]
武田fasiglifam (TAK-875)宣告失敗,恒瑞呋格列泛齒亡唇寒 已有16人參與
|
|||
|
Takeda terminates development activities for fasiglifam (TAK-875) Takeda Pharmaceutical Company Limited (Takeda) announced that it has decided voluntarily to terminate the development activities for fasiglifam (TAK-875), an investigational treatment for type 2 diabetes, due to concerns about liver safety. Patient safety is Takeda's highest priority. The company has worked with three independent panels of experts to provide for the safety of trial participants and ensure independent safety oversight for the clinical trials throughout the duration of the fasiglifam (TAK-875) Phase 3 development program. The expert panels include the independent Data Monitoring Committee (DMC), a committee that oversees the fasiglifam global clinical development program, reviews the unblinded clinical data from program trials and provides continual safety oversight of trial subjects and recommendations. The DMC is comprised of clinical experts in endocrinology, cardiology and hepatology as well as a statistician. The independent Liver Safety Evaluation Committee (LSEC) is comprised of five hepatologists with expertise in drug-induced liver injury. While remaining blinded to treatment information, the LSEC regularly evaluates data on liver enzymes elevations and adjudicates cases that impacted the liver. In addition, an independent Executive Committee (EC) provides additional oversight for the fasiglifam (TAK-875) cardiovascular outcomes trial. After careful consideration of the data emerging from all the clinical trials and in consultation with these panels, the company has reached the conclusion that, on balance, the benefits of treating patients with fasiglifam (TAK-875) do not outweigh the potential risks. For this reason, Takeda has decided voluntarily to terminate the development activities for fasiglifam. 作為慢性疾。禾悄虿〉闹委,肝毒性太致命了,難怪武田揮淚斬馬謖。值得一提的是,恒瑞也向CFDA申報(bào)了GPR-40激動(dòng)劑呋格列泛,現(xiàn)在心里估計(jì)也是拔涼拔涼的 |
新藥仿藥 |
鐵蟲 (初入文壇)
銅蟲 (小有名氣)
木蟲 (著名寫手)
muchong

木蟲 (著名寫手)
| 哎。。。。。! |
鐵桿木蟲 (小有名氣)
新蟲 (小有名氣)
金蟲 (正式寫手)
版主 (知名作家)
搬磚將

| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 288求調(diào)劑,一志愿華南理工大學(xué)071005 +5 | ioodiiij 2026-03-17 | 5/250 |
|
|---|---|---|---|---|
|
[考研] 梁成偉老師課題組歡迎你的加入 +9 | 一鴨鴨喲 2026-03-14 | 11/550 |
|
|
[考研] 085600材料與化工調(diào)劑 324分 +10 | llllkkkhh 2026-03-18 | 12/600 |
|
|
[考研] 求調(diào)劑,一志愿:南京航空航天大學(xué)大學(xué) ,080500材料科學(xué)與工程學(xué)碩,總分289分 +3 | @taotao 2026-03-19 | 3/150 |
|
|
[考研] 287求調(diào)劑 +3 | 晨昏線與星海 2026-03-19 | 4/200 |
|
|
[考研] 354求調(diào)劑 +4 | Tyoumou 2026-03-18 | 7/350 |
|
|
[考研] 085600材料與化工 +5 | 安全上岸! 2026-03-16 | 5/250 |
|
|
[考研] 311求調(diào)劑 +6 | 26研0 2026-03-15 | 6/300 |
|
|
[考研] 0703化學(xué)調(diào)劑 +3 | 妮妮ninicgb 2026-03-17 | 3/150 |
|
|
[考研] 工科材料085601 279求調(diào)劑 +6 | 困于星晨 2026-03-17 | 6/300 |
|
|
[考研] 301求調(diào)劑 +9 | yy要上岸呀 2026-03-17 | 9/450 |
|
|
[考研] 302求調(diào)劑 +4 | 小賈同學(xué)123 2026-03-15 | 8/400 |
|
|
[考研] 283求調(diào)劑 +3 | 聽風(fēng)就是雨; 2026-03-16 | 3/150 |
|
|
[考研] 一志愿211 0703方向310分求調(diào)劑 +3 | 努力奮斗112 2026-03-15 | 3/150 |
|
|
[考研] 26考研一志愿中國石油大學(xué)(華東)305分求調(diào)劑 +3 | 嘉年新程 2026-03-15 | 3/150 |
|
|
[考研] 0856專碩279求調(diào)劑 +5 | 加油加油!? 2026-03-15 | 5/250 |
|
|
[考研] 070305求調(diào)劑 +3 | mlpqaz03 2026-03-14 | 4/200 |
|
|
[考研] 中科大材料與化工319求調(diào)劑 +3 | 孟鑫材料 2026-03-14 | 3/150 |
|
|
[考研] 328求調(diào)劑 +3 | 5201314Lsy! 2026-03-13 | 6/300 |
|
|
[碩博家園] 085600 260分求調(diào)劑 +3 | 天空還下雨么 2026-03-13 | 5/250 |
|